Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.
Malik SM, Pazdur R, Abrams JS, Socinski MA, Sause WT, Harpole DH Jr, Welch JJ, Korn EL, Ullmann CD, Hirsch FR. Malik SM, et al. Among authors: socinski ma. J Thorac Oncol. 2014 Oct;9(10):1443-8. doi: 10.1097/JTO.0000000000000314. J Thorac Oncol. 2014. PMID: 25521397 Free PMC article.
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
Lynch TJ Jr, Blumenschein GR Jr, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Lynch TJ Jr, et al. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12. doi: 10.1097/JTO.0b013e318174e9d3. J Thorac Oncol. 2008. PMID: 18520291 Free article.
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Lilenbaum R, Villaflor VM, Langer C, O'Byrne K, O'Brien M, Ross HJ, Socinski M, Oldham FB, Sandilac L, Singer JW, Bonomi P. Lilenbaum R, et al. J Thorac Oncol. 2009 Jul;4(7):869-74. doi: 10.1097/JTO.0b013e3181a9a020. J Thorac Oncol. 2009. PMID: 19487960 Free article.
Fibroblastic growth factor pathway.
Socinski MA. Socinski MA. J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1066-7. doi: 10.1097/01.JTO.0000361753.86918.40. J Thorac Oncol. 2009. PMID: 19861920 Free article. No abstract available.
RET rearrangements in lung adenocarcinoma and radiation.
Dacic S, Luvison A, Evdokimova V, Kelly L, Siegfried JM, Villaruz LC, Socinski MA, Nikiforov YE. Dacic S, et al. Among authors: socinski ma. J Thorac Oncol. 2014 Jan;9(1):118-20. doi: 10.1097/JTO.0000000000000015. J Thorac Oncol. 2014. PMID: 24346100 Free PMC article.
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA; Alliance for Clinical Trials in Oncology. Heist RS, et al. Among authors: socinski ma. J Thorac Oncol. 2014 Feb;9(2):214-21. doi: 10.1097/JTO.0000000000000071. J Thorac Oncol. 2014. PMID: 24419419 Free PMC article. Clinical Trial.
341 results